Protox Successfully Doses First Patient in Prostate Cancer Trial Using PRX302
Tuesday, May 2, 2006 - Vancouver, British Columbia - Protox Therapeutics Inc. (TSX-V: PRX) today announced the enrollment and successful dosing of the first patient in a Phase I clinical study evaluating their lead drug, PRX302, to treat localized recurrent prostate cancer.

Login to read more...

Content on UroToday and UroToday International Journal is copyrighted and can be used for personal, noncommercial use only. You can order presentation-ready copies for distribution to your colleagues, clients or customers by emailing UroToday at commercialreprints@urotoday.com. Request a reprint quote of this article now, please include the title of the article and number or copies requested.

UroToday, 1802 Fifth Street, Berkeley CA 94710 510.540.0930 (fax), info@urotoday.com ISSN 1939-4810 UroToday International Journal Correspondence About The Editors | About Us | Contact Us | Report an Inaccuracy | Sponsorship Opportunities | Terms of Use Privacy Policy | © 2010 Digital Science Press, Inc ® All Rights Reserved